A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours

ABTL0812 is an autophagy inducer that promotes cancer cell death by activation of cytotoxic autophagy selectively in tumour cells. ABTL0812 induces endoplasmic reticulum stress and blocks the Akt-mTOR axis; both actions converge to activate a robust and sustained autophagy leading to cancer cell death. Preclinical data supported the initiation of clinical trials in patients with cancer.

Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Laura Vidal, Ivan Victoria, Lydia Gaba, Marta Gil Mart ín, Mercè Brunet, Helena Colom, Marc Cortal, Mariana Gómez-Ferrería, Marc Yeste-Velasco, Antonio Perez, Jordi Rodon, Davendra P.S. Sohal, José Miguel Lizcano, Carles Domènech, José Alfón, Pere Tags: Original Research Source Type: research